Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.

Smesny S, Milleit B, Hipler UC, Milleit C, Schäfer MR, Klier CM, Holub M, Holzer I, Berger GE, Otto M, Nenadic I, Berk M, McGorry PD, Sauer H, Amminger GP.

Mol Psychiatry. 2014 Mar;19(3):317-24. doi: 10.1038/mp.2013.7. Epub 2013 Mar 12.

PMID:
23478748
2.

Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids.

Amminger GP, Mechelli A, Rice S, Kim SW, Klier CM, McNamara RK, Berk M, McGorry PD, Schäfer MR.

Transl Psychiatry. 2015 Jan 13;5:e495. doi: 10.1038/tp.2014.134.

3.

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE.

Arch Gen Psychiatry. 2010 Feb;67(2):146-54. doi: 10.1001/archgenpsychiatry.2009.192.

PMID:
20124114
4.

Frontal delta power associated with negative symptoms in ultra-high risk individuals who transitioned to psychosis.

Lavoie S, Schäfer MR, Whitford TJ, Benninger F, Feucht M, Klier CM, Yuen HP, Pantelis C, McGorry PD, Amminger GP.

Schizophr Res. 2012 Jul;138(2-3):206-11. doi: 10.1016/j.schres.2012.03.033. Epub 2012 Apr 19.

PMID:
22520856
5.

Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.

McGorry PD, Nelson B, Markulev C, Yuen HP, Schäfer MR, Mossaheb N, Schlögelhofer M, Smesny S, Hickie IB, Berger GE, Chen EY, de Haan L, Nieman DH, Nordentoft M, Riecher-Rössler A, Verma S, Thompson A, Yung AR, Amminger GP.

JAMA Psychiatry. 2017 Jan 1;74(1):19-27. doi: 10.1001/jamapsychiatry.2016.2902.

PMID:
27893018
6.

Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial.

Amminger GP, Chanen AM, Ohmann S, Klier CM, Mossaheb N, Bechdolf A, Nelson B, Thompson A, McGorry PD, Yung AR, Schäfer MR.

Can J Psychiatry. 2013 Jul;58(7):402-8.

PMID:
23870722
7.

Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study.

Kim SW, Jhon M, Kim JM, Smesny S, Rice S, Berk M, Klier CM, McGorry PD, Schäfer MR, Amminger GP.

PLoS One. 2016 Mar 10;11(3):e0151417. doi: 10.1371/journal.pone.0151417. eCollection 2016.

8.

Polyunsaturated fatty acids in emerging psychosis: a safer alternative?

Schlögelhofer M, Amminger GP, Schaefer MR, Fusar-Poli P, Smesny S, McGorry P, Berger G, Mossaheb N.

Early Interv Psychiatry. 2014 Aug;8(3):199-208. doi: 10.1111/eip.12151. Epub 2014 May 27. Review.

PMID:
24861004
9.

Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?

Mossaheb N, Schäfer MR, Schlögelhofer M, Klier CM, Cotton SM, McGorry PD, Amminger GP.

Schizophr Res. 2013 Aug;148(1-3):163-7. doi: 10.1016/j.schres.2013.05.027. Epub 2013 Jun 15.

PMID:
23778032
10.

Erythrocyte polyunsaturated fatty acid levels in young people at ultra-high risk for psychotic disorder and healthy adolescent controls.

Rice SM, Schäfer MR, Klier C, Mossaheb N, Vijayakumar N, Amminger GP.

Psychiatry Res. 2015 Jul 30;228(1):174-6. doi: 10.1016/j.psychres.2015.04.036. Epub 2015 May 2.

PMID:
25979466
11.

Correlates of electroencephalographic resting states and erythrocyte membrane docosahexaenoic and eicosapentaenoic acid levels in individuals at ultra-high risk of psychosis.

Lavoie S, Whitford TJ, Benninger F, Feucht M, Kim SW, Klier CM, McNamara RK, Rice S, Schäfer MR, Amminger GP.

Aust N Z J Psychiatry. 2016 Jan;50(1):56-63. doi: 10.1177/0004867415571168. Epub 2015 Feb 17.

PMID:
25690743
12.

Polyunsaturated fatty acid supplementation for drug-resistant epilepsy.

Sarmento Vasconcelos V, Macedo CR, de Souza Pedrosa A, Pereira Gomes Morais E, Porfírio GJ, Torloni MR.

Cochrane Database Syst Rev. 2016 Aug 17;(8):CD011014. doi: 10.1002/14651858.CD011014.pub2. Review.

PMID:
27536971
13.

NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.

Markulev C, McGorry PD, Nelson B, Yuen HP, Schaefer M, Yung AR, Thompson A, Berger G, Mossaheb N, Schlögelhofer M, Smesny S, de Haan L, Riecher-Rössler A, Nordentoft M, Chen EY, Verma S, Hickie I, Amminger GP.

Early Interv Psychiatry. 2015 Aug 16. doi: 10.1111/eip.12260. [Epub ahead of print]

PMID:
26279065
14.

Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids.

Mossaheb N, Papageorgiou K, Schäfer MR, Becker J, Schloegelhofer M, Amminger GP.

Early Interv Psychiatry. 2015 Sep 11. doi: 10.1111/eip.12275. [Epub ahead of print]

PMID:
26362578
15.

Effects of omega-3 PUFA on the vitamin E and glutathione antioxidant defense system in individuals at ultra-high risk of psychosis.

Smesny S, Milleit B, Schaefer MR, Hipler UC, Milleit C, Wiegand C, Hesse J, Klier CM, Holub M, Holzer I, Berk M, McGorry PD, Sauer H, Amminger GP.

Prostaglandins Leukot Essent Fatty Acids. 2015 Oct;101:15-21. doi: 10.1016/j.plefa.2015.07.001. Epub 2015 Jul 21.

PMID:
26260538
16.

Altered erythrocyte membrane fatty acid profile in typical Rett syndrome: effects of omega-3 polyunsaturated fatty acid supplementation.

Signorini C, De Felice C, Leoncini S, Durand T, Galano JM, Cortelazzo A, Zollo G, Guerranti R, Gonnelli S, Caffarelli C, Rossi M, Pecorelli A, Valacchi G, Ciccoli L, Hayek J.

Prostaglandins Leukot Essent Fatty Acids. 2014 Nov;91(5):183-93. doi: 10.1016/j.plefa.2014.08.002. Epub 2014 Sep 6.

PMID:
25240461
17.

A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia.

Bentsen H, Osnes K, Refsum H, Solberg DK, Bøhmer T.

Transl Psychiatry. 2013 Dec 17;3:e335. doi: 10.1038/tp.2013.110.

19.

Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study.

Amminger GP, Schäfer MR, Schlögelhofer M, Klier CM, McGorry PD.

Nat Commun. 2015 Aug 11;6:7934. doi: 10.1038/ncomms8934.

20.

Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients.

Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Sobajic S, Djuric I, Ristic D.

Ren Fail. 2007;29(3):321-9.

PMID:
17497447

Supplemental Content

Support Center